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Abstract 
Purpose: FOLFOX is a standard combination chemotherapy regimen for metastatic colorectal cancer (CRC). 5-Fluo-
rouracil (5-FU) is infused continuously through a pump for 46 h; therefore, replacement of infused 5-FU with oral S-1 
would be more convenient for patients. We investigated the efficacy and safety of S-1/oxaliplatin (SOX) plus bevaci-
zumab regimen in a community setting.
Methods: We conducted a phase II clinical study in Hiroshima, Japan. We enrolled individuals aged 20–80 years who 
had metastatic CRC, an Eastern Cooperative Oncology Group performance status of 0 or 1, assessable lesions, and not 
received previous chemotherapy. Eligible patients were administered SOX plus bevacizumab (S-1 80 mg/m2/day, day 
1–14 orally; and oxaliplatin 130 mg/m2 day 1 i.v., bevacizumab 7.5 mg/kg, day 1 i.v. q3w). The primary endpoint was 
response rate (RR), and the secondary endpoints were progression-free survival (PFS), overall survival (OS), and safety.
Results: Between May 2011 and January 2014, 55 patients (mean age 64 years) were enrolled at 12 institutions. 
Median follow up duration was 20.2 months (range 1.3–47.1 months). RR was 47.1 % [95 % confidence interval (CI) 
33.7–60.6 %]. Median PFS and OS was 9.2 months (95 % CI 7.6–10.8) and 22.5 months (95 % CI 19.4–25.9), respectively. 
Major adverse events (grade 3/4) were neutropenia (9.3 %), thrombocytopenia (5.6 %), anorexia (18.5 %), and sensory 
neuropathy (16.7 %).
Conclusion: These data suggested that SOX plus bevacizumab is effective and capable of being managed in meta-
static CRC patients in our community clinical practice.
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Introduction
The combination chemotherapies, FOLFOX (5-fluoro-
uracil [5-FU], leucovorin, and oxaliplatin) and FOLFIRI 
(5-FU, leucovorin, and irinotecan), have been the most 
common first-line metastatic colorectal cancer (CRC). 
Targeted agents that enhance the effect of chemotherapy 
have been discovered, including bevacizumab (a human-
ized monoclonal antibody that targets vascular endothe-
lial growth factor, a central regulator of angiogenesis), 
cetuximab and panitumumab (monoclonal antibodies 
directed against the epidermal growth factor receptor) 
(Hurwitz et al. 2004; Van Cutsem et al. 2009).
FOLFOX with bevacizumab is widely used in clinical 
practice as the first line treatment for metastatic CRC 
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(Goldberg et  al. 2004). However, this regimen is incon-
venient owing to its requirement for continuous infu-
sion via vascular access. To overcome this drawback, oral 
fluoropyrimidines, such as capecitabine, have been used 
as a substitute for infused leucovorin and fluorouracil. 
Recent data have demonstrated that capecitabine and 
oxaliplatin plus bevacizumab is non-inferior to FOLFOX 
plus bevacizumab regimen considering progression-free 
survival (PFS) of patients with metastatic CRC (Cassidy 
et al. 2008; Saltz et al. 2008).
Another oral fluorouracil, S-1, is a chemotherapy 
agent that consists of tegafur (a pro-drug of 5-FU) and 
two agents, gimeracil and oteracil, which decrease the 
rate of degradation of 5-FU anti-metabolite. S-1 could 
have advantages over capecitabine in terms of reducing 
the frequency of toxicities such as hand-foot syndrome 
(HFS), and several trials have shown the feasibility and 
efficacy of S-1/oxaliplatin (SOX) for metastatic CRC 
(Yamada et al. 2008; Zang et al. 2009). However, there is 
still a lack of sufficient evidence of efficacy and safety for 
this new treatment regimen to become a standard choice 
in clinical practice.
Accordingly, we conducted a multicenter clinical phase 
II trial across 12 institutions in Hiroshima, Japan (the 
Hiroshima Surgical study group of Clinical Oncology; 
HiSCO). We aimed to investigate the efficacy and safety 
of SOX plus bevacizumab, a promising alternative treat-
ment for metastatic CRC.
Patients and methods
Patient selection
We undertook an open-label, non-randomized, mul-
ticenter clinical phase II trial in 12 institutions in Hiro-
shima, Japan. We enrolled individuals who met the 
following eligibility criteria: (1) histologically proven 
colorectal adenocarcinoma; (2) unresectable advanced/
metastatic CRC; (3) aged 20–80 years; (4) Eastern Coop-
erative Oncology Group performance status (PS) of 0 
or 1; (5) presence of assessable lesions as confirmed on 
computed tomography or magnetic resonance imaging; 
(6) no previous chemotherapy or radiotherapy; (7) could 
take drugs orally; (8) adequate hematological, renal, and 
hepatic functions, as defined by a leucocyte count of 
3–12 ×  109/L; neutrophil count of at least 2.0 ×  109/L; 
platelet count of at least 100 ×  109/L; hemoglobin level 
of at least 9.0  g/dL; total serum bilirubin concentration 
of no more than 1.5 mg/dL; serum aspartate aminotrans-
ferase/serum alanine aminotransferase concentration of 
no more than 100  U/L; serum creatinine concentration 
of no more than 1.2 mg/dL; creatinine clearance >60 mL/
min; urinary protein score of no more than 1+; and an 
international normalized ratio of no more than 1.5 and 
(9) estimated life expectancy of >3 months.
We excluded individuals if they had a history of seri-
ous allergies to any medications, active infections, serious 
concurrent disease, substantially impaired cardiac func-
tion, gastrointestinal ulcers or bleeding, sensory neurop-
athy, serious diarrhea, ascites or pleural effusion needing 
medication, brain metastases, a history of gastrointesti-
nal perforation within the 6 months before enrollment, a 
history of thromboembolism or interstitial pneumonia, a 
history of surgery within the 28 days before enrollment, 
a blood coagulation disorder, were on anticoagulation 
medication, a history of hemoptysis, or had a primary 
lesion associated with a severe stricture that precluded 
passage of an endoscope. We also excluded individuals if 
they had previously or were presently receiving oxalipl-
atin-based regimens as adjuvant chemotherapy.
The current study was conducted in accordance with 
the declaration of Helsinki. All patients provided writ-
ten informed consent after having been informed about 
the purpose and investigational nature of the study. The 
institutional review boards or ethics committees of each 
of the participating centers reviewed and approved the 
protocol. This study was registered in the UMIN Clinical 
Trial Registry as UMIN000004976.
Treatment
On day 1 of each 3-week cycle, patients assigned to 
receive SOX plus bevacizumab received a 7.5  mg/kg 
intravenous infusion of bevacizumab (for 30–90  min), 
followed by an intravenous infusion of 130 mg/m2 oxali-
platin (for 2 h). S-1 was taken orally twice daily from after 
dinner on day 1 to after breakfast on day 15, followed by 
a 7-day break. The dose of S-1 was assigned according 
to body surface area: patients with a body surface area 
of less than 1.25  m2 received 80  mg/day; those with a 
body surface area between 1.25 m2 and less than 1.5 m2 
received 100  mg/day; and those with a body surface 
area of at least 1.5 m2 received 120 mg/day. Cycles were 
repeated for each patient until the criteria for withdrawal 
of the study treatment were met.
In view of the neurological toxicity of oxaliplatin, 
treatment could be skipped when patients had received 
at least 600  mg/m2 overall, even when no grade 3 toxic 
effects were recorded. If patients had grade 2 or higher 
proteinuria or grade 2 or higher bleeding before the 
scheduled starting day of each cycle, they received only 
SOX treatment; bevacizumab could be resumed in sub-
sequent cycles if the treatment criteria were satisfied. 
The dose of cytotoxic drugs (oxaliplatin and S-1) was 
reduced by one level if the neutrophil count was less than 
0.5  ×  109/L at any time during a cycle, the neutrophil 
count was less than 1.0 × 109/L on the first day of a cycle, 
grade 3 or higher febrile neutropenia developed, or the 
platelet count was less than 50 × 109/L. In the event of 
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grade 3 or higher diarrhea, the dose of S-1 was reduced 
by one level. If the platelet count was between 50 × 109 
and 75 ×  109/L at any time during a cycle, or between 
75 × 109 and 100 × 109/L on the first day of a cycle, the 
oxaliplatin dose was reduced by one level. S-1 was with-
held when the neutrophil count was less than 1 × 109/L; 
the platelet count was less than 75 ×  109/L; the serum 
creatinine concentration was more than 1.5 mg/dL; sus-
pected infection was diagnosed due to a fever of at least 
38 °C; or diarrhea, mucositis, or stomatitis of grade 2 or 
higher developed. S-1 was subsequently reinitiated when 
the neutrophil count was at least 1 × 109/L; the platelet 
count was at least 75 × 109/L; the serum creatinine con-
centration was less than 1.5 mg/dL; no fever of 38 °C or 
higher suggesting infection was evident; and diarrhea, 
mucositis, and stomatitis were no higher than grade 1.
Endpoints
The primary endpoint of this study was response rate 
(RR), and the secondary endpoints were PFS, overall sur-
vival (OS), and safety.
RR was calculated for patients who had measurable 
lesions using the Response Evaluation Criteria in Solid 
Tumor (RECIST; version 1.1) (Eisenhauer et  al. 2009). 
RR and disease control rate (DCR) were analyzed for 
the patients with target lesions. After initiation of study 
treatment, target and non-target lesions were assessed 
every 8 weeks in the same way as at baseline, using the 
same imaging conditions.
PFS was defined as the interval from the date of enroll-
ment to the date on which progressive disease was first 
confirmed or the date of death from any cause, which-
ever came first. OS was defined as the interval from the 
date of enrollment to the date of death from any cause 
or last follow-up. Adverse events were graded according 
to the Common Terminology Criteria for Adverse Events 
(CTCAE; version 4.0).
We also evaluated the proportion of patients achiev-
ing disease control (a complete or partial response or 
stable disease), the proportion of patients having a cura-
tive resection, the time to treatment failure (TTF, interval 
from the date of enrolment to the date of a PFS event or 
withdrawal from the study for any reason), and adverse 
events.
Statistical analysis
All endpoints analyses except for the safety analysis were 
performed on the intent-to-treat set. The safety analy-
sis included all treated patients who received at least 
one dose of the experimental drug. The required sam-
ple size was calculated to be at least 55 patients on the 
null hypothesis of a RR of 30  % versus the alternative 
hypothesis of a RR of 50 %, with a power of 80 %, and a 
95 % significance level (one sided). Survival curves were 
estimated using the Kaplan–Meier method. All statisti-




Between May 2011 and January 2014, 55 patients were 
enrolled in this study. Patient characteristics are listed in 
Table 1. The mean age was 64 years. Forty-nine patients 
had a PS of 0, and 6 had a PS of 1. Of the 55 patients, 
37 underwent primary tumor resection (67.3 %), and 12 
underwent adjuvant chemotherapy (21.8 %). The number 
of organs with metastatic lesions was one in 29 patients 
(52.7 %) and two or more in 25 patients (45.4 %), and 2 
patients had no assessable lesions (3.6  %). The median 
follow-up duration was 20.2 months (range 1.3–47.1).
Efficacy
One patient did not meet the eligibility criteria because 
of the absence of recurrent disease. Treatment was per-
manently stopped before the first tumor response evalu-
ation for 4 patients owing to withdrawal of consent by 
1 and owing to adverse events in the other 3 (grade 2 
deep vein thrombosis in 1 patient, grade 3 anorexia in 1 
patient, grade 4 neutropenia in 1 patient). In total, 472 
treatment cycles were administered with a median of 7.5 
cycles (range 0–34) per patient. S-1 was administrated in 
472 cycles, oxaliplatin was administrated in 392 cycles, 
and bevacizumab was administrated in 423 cycles.
The tumor response data are listed in Table  2. RR was 
47.1  % [95  % confidence interval (CI) 33.7–60.6  %], and 
therefore, the primary endpoint was achieved. DCR 
was 88.7 % (95 % CI 80.1–97.2 %), and median TTF was 
6.3 months (95 % CI 4.0–8.5 months). RR and DCR were 
analyzed for the patients with assessable lesions. A cura-
tive R0 resection was performed in 4 patients (7.4  %). A 
waterfall plot of the best overall response is demonstrated 
in Fig. 1.
Median PFS was 9.2  months (95  % CI 7.5–10.9, 
Fig. 2), and median OS was 22.5 months (95 % CI 19.4–
25.9 months, Fig. 3).
Safety
The safety analysis included all treated patients who 
received at least one dose of the experimental drug 
(n = 54). The adverse events are listed in Table 3. Major 
hematological adverse events (grade 3/4) were neutro-
penia (9.3 %), thrombocytopenia (5.6 %), and leucopenia 
(5.6  %). Major non-hematological adverse events (grade 
3/4) were hypertension (22.2  %), anorexia (18.5  %), and 
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sensory neuropathy (16.7 %). The toxic effects were capa-
ble of being managed; however, attention to the occur-
rence of anorexia was needed.
The median relative dose intensities (RDIs; ratio of 
dose received to dose planned) are listed in Table 4. The 
median RDI of oxaliplatin, S-1, and bevacizumab was 84, 
88, and 90 %, respectively.
Discussion
We herein demonstrated that SOX plus bevacizumab 
is effective and capable of being managed in metastatic 
CRC patients in our community clinical practice.
The combination of chemotherapeutic regimens and 
the development of molecular targeted agents lead to 
improved survival in metastatic CRC. In order to develop 
new chemotherapeutic regimens, it is important to con-
sider not only the survival benefit but also the mainte-
nance of the quality of life of patients. S-1 is an effective 
derivative that combines tegafur with two modulators 
of 5-FU metabolism, gimeracil, a reversible inhibitor 
of dihydropyrimidine dehydrogenase, and oteracil in a 
molar ratio of 1:0.4:1. Gimeracil maintains a high fluo-
rouracil concentration in the blood for a long time, and 
oteracil inhibits the conversion of 5-FU to active metabo-
lites in the gastrointestinal tract, resulting in a reduction 
in gastrointestinal toxicity (Kato et  al. 2001; Shirasaka 
2009). S-1 was originally approved for the treatment of 
gastric cancer in Japan in 1999, and subsequently gained 
Japanese approval for CRC in 2003. More recently, there 
Table 1 Baseline patient characteristics (n = 55)





















Yes (%) 12 (21.8 %)
Uracil and tegafur plus leucovorin 5
Capecitabine 5
5-FU/LV 1
Uracil and tegafur 1







Lymph node metastases 13
Peritoneal dissemination 4
other metastases 11




Liver limited disease (%) 14 (25.4 %)
CEA (median, range) 21.2 (2.3–8577.6)
CA19-9 (median, range) 38.8 (0.7–328,230)
Table 2 Treatment outcomes
a Response rate and disease control rate were analyzed for the patients with 
assessable lesion










Response rate (%) 25 (47.1 %) 33.7–60.6






















Fig. 1 Waterfall plot analysis of the best overall response in the inten-
tion to treat set. CR complete response; PR partial response; SD stable 
disease; PD progressive disease
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has been a shifting paradigm in cancer care towards oral 
chemotherapeutics. In the view of the convenience oral 
dosing offers to both patients and physicians, S-1 was 
gradually accepted as an alternative therapy to infused 
FU, similar to capecitabine (Muro et  al. 2010; Yoshida 
et al. 2014). S-1 has the potential to improve accessibility 
to chemotherapy and decrease serious patient toxicities 
such as HFS. Placement of an ambulatory infusion pump 
is not absolutely necessary for patients treated with SOX 
plus bevacizumab. In our study, 33.3  % of the patients 
(n  =  18) did not need an implanted port placement. 
Additionally, patients who received SOX plus bevaci-
zumab returned to the hospital only once every 3 weeks. 
Thus, this new regimen is a promising treatment option 
to replace FOLFOX6 plus bevacizumab regimen, particu-
larly for maintaining the quality of life of the patients.
In the phase I/II study of SOX regimen as the first-line 
treatment for metastatic CRC in Japan, Yamada et  al. 
showed a RR of 50  % and a median PFS of 6.4  months 
(Yamada et al. 2008). In the phase II study of SOX regi-
men in Korea, Zang et al. (2009) showed a RR of 54 % and 
a median PFS of 8.5 months. A phase III study in South 
Korea showed that SOX is non-inferior to capecitabine 
plus oxaliplatin, with a RR of 47 % and a median PFS of 
8.5  months (Hong et  al. 2012). Based on the results of 
these previous studies, we hypothesized the expected and 
threshold RRs of 50 and 30 %, respectively, used to design 
our study.
More recently, SOFT trial demonstrated the non-infe-
riority of SOX plus bevacizumab to mFOLFOX6 plus 
bevacizumab, with a RR of 61.5 % and a median PFS of 
10.2  months (Yamada et  al. 2013). In the present study, 
the RR was 47.1 % (95 % CI 33.7–60.6 %), achieving the 
primary endpoint, and the median PFS was 9.2  months 
(95  % CI 7.6–10.8  months, Fig.  1). Recent clinical trials 
have reported the median OS to be more than 30 months 
(Yamada et  al. 2013; Schwartzberg et  al. 2014). In this 
study, the median OS was 22.5  months (95  % CI 19.4–
25.9 months). Additional investigation into the OS in the 
future is necessary, because our median follow-up dura-
tion was only 20.2 months.
The toxicity profile of SOX plus bevacizumab is known 
to be different from that of mFOLFOX6 and XELOX 
(capecitabine/oxaliplatin). In the present study, the fre-
quency of severe (grade 3/4) hematological toxicities 
including thrombocytopenia were low; however, the 
occurrence of anorexia was high (18.5 %). HFS was rarely 
observed in the present study. The occurrence of sensory 
neuropathy was 16.7 %, which was almost equivalent to 
that occurring after the administration of FOLFOX6 or 
XELOX. The incidence of serial complications related 
to bevacizumab, such as venous thrombosis, gastroin-
testinal perforation, and bleeding complications, was 
extremely low. The occurrence of hypertension was high 
(grade 3/4, 22.2 %); therefore, medical management was 
needed. Generally, adverse events were capable of being 
managed in the present study; however, attention to the 
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Fig. 2 Kaplan-Meier curves for progression-free survival (PFS); the 
median PFS was 9.2 months (95 % confidence interval: 7.6–10.8) N. at 
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(95%CI 19.4 - 25.9)
months
Fig. 3 Kaplan-Meier curves for overall survival (OS); the median OS 
was 22.5 months (95 % confidence interval 19.4–25.9 months) N. at 
risk, number at risk
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In the present study, the median RDI of oxaliplatin, S-1, 
and bevacizumab was 88, 84, and 90 %, respectively. In the 
phase I/II study of the SOX regimen in Japan, the median 
RDI of oxaliplatin and S-1 was 82.8 and 74.6 %, respectively 
(Yamada et al. 2008). In the phase II study of the SOX regi-
men in Korea, the median RDI of oxaliplatin and S-1 was 
82 and 82 %, respectively (Zang et al. 2009). In a phase III 
study in South Korea, the median RDI of oxaliplatin and 
S-1 was 88 and 93  %, respectively (Hong et  al. 2012). In 
SOFT trial, the median RDI of oxaliplatin, S-1, and beva-
cizumab was 75.5, 79.9, and 88.5 %, respectively (Yamada 
et al. 2013). These results suggest an almost equivalent RDI 
of the present study to those in previous studies.
SOFT trial already showed the non-inferiority of SOX 
plus bevacizumab to mFOLFOX6 plus bevacizumab in a 
full analysis set without patients with peritoneal dissemi-
nations (Yamada et al. 2013). The new finding of our pre-
sent study was that the primary endpoint was achieved 
in an intention to treat set including patients with perito-
neal dissemination (four patients). The efficacy and safety 
of the SOX plus bevacizumab regimen was also demon-
strated in this prospective multicenter phase II trial con-
ducted in 12 institutions that play a major role in regional 
medicine in Hiroshima, Japan.
In conclusion, the SOX plus bevacizumab regimen is 
effective and capable of being managed in patients with 
advanced/metastatic CRC in our community clinical 
practice, and is an option for treatment to replace the 
FOLFOX plus bevacizumab regimen.
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Table 3 Relative dose intensity
Drugs Cycles Median (%) Range (%)
S-1 472 84 23–100
Oxaliplatin 392 88 52–100
Bevacizumab 423 90 31–100
Table 4 Safety analysis (n = 54)
Any grade >Grade3
n (%) n (%)
Haematological
Leucopenia 30 (55.6) 3 (5.6)
Neutropenia 30 (55.6) 5 (9.3)
Thrombocytopenia 35 (61.1) 3 (5.6)
Increased aspartate aminotransferase or alanine 
aminotransferase concentration
33 (61.1) 0 (0)
Increased creatinine concentration 8 (14.8) 0 (0)
Proteinurea 20 (37) 0 (0)
Non-haematological
Mucositis or stomatitis 16 (29.6) 1 (1.9)
Anorexia 38 (70.4) 10 (18.5)
Nausea 16 (29.6) 3 (5.6)
Vomiting 10 (18.5) 0 (0)
Diarrhoea 16 (29.6) 0 (0)
Rash or desquamation 11 (20.4) 0 (0)
Hyperpigmentation 14 (25.9) 0 (0)
Fatigue 36 (68.7) 1 (1.9)
Sensory neuropathy 37 (68.5) 9 (16.7)
Hypertension 46 (85.2) 12 (22.2)
Alopecia 1 (1.9) 0 (0)
Hand-foot syndrome 8 (14.8) 0 (0)
Gastroinetestinal obstrucion 4 (7.4) 3 (5.6)
Gastrointestinal perforation 0 (0) 0 (0)
Fever 4 (7.4) 1 (1.9)
Thrombosis, thrombus, or embolism 2 (3.8) 1 (1.9)
Bleeding complication 5 (9.2) 1 (1.8)
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